Results 61 to 70 of about 3,654 (190)

Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

Infection and Drug Resistance, 2019
Lindsey M Childs-Kean, Natalie A Brumwell, Emma F LodlDepartment of Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL, USAAbstract: The treatment of chronic hepatitis C has been revolutionized with the
Childs-Kean LM, Brumwell NA, Lodl EF
doaj  

Potential interactions between pangenotypic direct-acting antivirals and concomitant cardiovascular therapies in patients with chronic hepatitis C virus infection

Journal of International Medical Research, 2020
Objective To identify potential drug interactions (DIs) between pangenotypic direct-acting antivirals (pDAAs) and concomitant cardiovascular (CV) therapies in patients with chronic hepatitis C (CHC).
Antoni Sicras-Mainar, Ramón Morillo-Verdugo   +1 more
doaj   +1 more source

Chronic hepatitis in horses with persistent equine hepacivirus infection

Equine Veterinary Journal, Volume 58, Issue 2, Page 444-457, March 2026.
Abstract Background Equine hepacivirus (EqHV) is closely related to hepatitis C virus (HCV), which causes persistent infection and chronic hepatitis in people. Information on persistent EqHV infection and hepatitis is limited. Objectives To report 19 cases of chronic hepatitis and persistent EqHV infection.
Mason C. Jager, Daniela Luethy, Samantha Shallop, Jessica Cathcart, Thomas J. Divers, Jean‐Yin Tan, Erin McConachie Beasley, Philip Johnson, Laurence Leduc, Claire Smith, Camilla Anne Jamieson, K. Gary Magdesian, Gerlinde R. Van de Walle, Joy E. Tomlinson   +13 more
wiley   +1 more source

Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C

, 2017
Objectives: To review the pharmacology, efficacy, and safety of sofosbuvir/velpatasvir in the treatment of patients with hepatitis C virus (HCV) infection.
Hemstreet, Brian, Chahine, Elias, Sucher, Allana J., Sucher, Allana, Chahine, Elias B., Hemstreet, Brian A.   +5 more
core   +1 more source

ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF SOFOSBUVIR AND VELPATASVIR DRUG PRODUCT BY REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD

, 2018
 Objectives: The purpose of the research is to develop a simple, precise, economical, accurate, reproducible, and sensitive method for the estimation of sofosbuvir and velpatasvir drug product by rp-hplc methodMethods: New Analytical method was ...
D, Ramachandran, Nekkala, Kalpana, J V, Shanmukha Kumar   +2 more
core   +2 more sources

Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection

, 2018
Introduction: Hepatitis C is a disease with a significant global impact. Over the last several years, the treatment of the disease has been revolutionized.
Santosh Kumar, Mu, Ying, Sunitha Kodidela, Kodidela, Sunitha, Gong, Yuqing, Cory, Theodore J., Ying Mu, Theodore J. Cory, Yuqing Gong, Kumar, Santosh   +9 more
core   +1 more source

Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use:The SIMPLIFY study [PDF]

, 2018
Background: This study investigated treatment adherence among people with recent injecting drug use in a study of sofosbuvir/velpatasvir therapy for HCV infection.Methods: SIMPLIFY is an international open-label, single-arm multicentre study that ...
Dunlop, Adrian J., Siriragavan, Sharmila, Conway, B., Matthews, Gail V, Dore, Gregory J, Amin, J., Litwin, A.H., Gane, Edward, Thurnheer, M.C., Norton, B., Litwin, Alain H., Cooper, Curtis, Hajarizadeh, Behzad, Dillon, John F.; id_orcid, Read, P., Conway, Brian, Applegate, Tanya L., Dillon, J.F., Gane, E., Bruggmann, Philip, Thurnheer Zürcher, Maria Christine, ?, ?, Fraser, Chris, Litwin, Alain H, Quiene, Sophie, Bruggmann, P., Shaw, David, Read, Phillip, et al., Thurnheer, Maria Christine, Dunlop, A.J., Hellard, Margaret, Amin, Janaki, Norton, Briana, Dalgard, O., Hellard, M., Weltman, M., Cunningham, Evan B, Feld, Jordan J., Powis, Jeff, Feld, Jordan J, Powis, J., Bruneau, J., Bruneau, Julie, Dunlop, Adrian J, Dore, Gregory J., Dalgard, Olav, Dillon, John F, Weltman, Martin, Marks, Philippa, Cooper, C., Grebely, Jason, Feld, J.J., Matthews, Gail V., Cunningham, Evan B., Hajarizadeh, B., Cunningham, E.B., Shaw, D., Applegate, Tanya L   +58 more
core   +1 more source

Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells

Scientific Reports, 2022
SARS coronavirus 2 (SARS-CoV-2) has caused an ongoing global pandemic with significant mortality and morbidity. At this time, the only FDA-approved therapeutic for COVID-19 is remdesivir, a broad-spectrum antiviral nucleoside analog.
Xammy Huu Wrynla, Eddie Wehri, Erik Van Dis, Scott B. Biering, Livia H. Yamashiro, Chi Zhu, Julien Stroumza, Claire Dugast-Darzacq, Thomas G. W. Graham, Xuanting Wang, Steffen Jockusch, Chuanjuan Tao, Minchen Chien, Wei Xie, Dinshaw J. Patel, Cindy Meyer, Aitor Garzia, Thomas Tuschl, James J. Russo, Jingyue Ju, Anders M. Näär, Sarah Stanley, Julia Schaletzky   +22 more
doaj   +1 more source

Bee products as alternatives in the treatment of viral infections

Journal of the Science of Food and Agriculture, Volume 106, Issue 1, Page 33-54, 15 January 2026.
Abstract Medicines used in the treatment of viral infections usually reduce symptoms. There is a need to develop drugs that inhibit the viruses and do not merely relieve the symptoms. Natural bee products possess many pharmacological properties and are widely used in folk medicine. There are many studies on the antibacterial effects of bee products but
Michał Otręba, Łukasz Marek, Jerzy Stojko, Anna Rzepecka‐Stojko   +3 more
wiley   +1 more source

Disrupting Viral Persistence: CRISPR/Cas9‐Based Strategies for Hepatitis B and C Treatment, and Challenges

Journal of Cellular and Molecular Medicine, Volume 30, Issue 1, January 2026.
ABSTRACT Hepatitis B and C viruses (HBV and HCV) remain among the leading causes of liver disease worldwide. Current antiviral drugs, such as nucleotide analogues (NAs), can reduce the replication of new HBV and HCV infections but cannot completely eliminate chronic infections.
Meng‐Fan Li, Akmal Zubair, Safa Wdidi, Shan He   +3 more
wiley   +1 more source